Related Experiment Video
Updated: Jun 23, 2026

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
FluBlok, a recombinant hemagglutinin influenza vaccine
Manon M J Cox1, Peter A Patriarca, John Treanor
1Protein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450, USA. manon.cox@proteinsciences.com
Abstract:
FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the 'Accelerated Approval' mechanism in the United States.
Related Concept Videos
Influenza
Leaky Scanning
Inhibitors Of Virion Release
Vaccinations

